We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo :...
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for...
Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités Au 31 mars 2024, trésorerie et équivalents de trésorerie à 11,0 millions d’euros...
Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH Le Data Monitoring Committee recommande sur la base...
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique...
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva...
Inventiva announces the nomination of Andre Turenne as Director Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the...
Inventiva reports its 2023 full-year results Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million...
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D LEGEND achieved its primary...
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 7.62 | 7.62 | 7.62 | 2 | 7.62 | DE |
4 | 0 | 0 | 7.62 | 7.62 | 7.62 | 93 | 7.62 | DE |
12 | 0 | 0 | 7.62 | 7.62 | 7.62 | 824 | 7.62 | DE |
26 | 0 | 0 | 7.62 | 7.62 | 7.62 | 1342 | 7.62 | DE |
52 | 0 | 0 | 7.62 | 7.62 | 7.62 | 4080 | 7.62 | DE |
156 | 0 | 0 | 7.62 | 7.62 | 7.62 | 2805 | 7.62 | DE |
260 | 0 | 0 | 7.62 | 7.62 | 7.62 | 4721 | 7.62 | DE |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.05 (132.82%) | 310.28M |
GWAVGreenwave Technology Solutions Inc | $ 0.0387 (-7.86%) | 305.13M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.584899 (3.47%) | 223.84M |
SQQQProShares UltraPro Short QQQ | $ 10.02 (0.00%) | 161.89M |
CRKNCrown Electrokinetics Corporation | $ 0.0998 (-12.07%) | 155.13M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions